Real-time enrollment status for this bladder cancer clinical trial
Current Status
Recruiting
Checked: October 15, 2026 at 12:00 PM UTC
| NCT Number | NCT04879329 |
| Recruiting Status | Recruiting |
| Condition | Bladder Cancer |
| Phase | PHASE2 |
| Target Enrollment | 372 participants |
| Active Locations | 158 sites in the US |
| Sponsor | Seagen, a wholly owned subsidiary of Pfizer |
| Last Updated on CT.gov | July 22, 2026 (Jul 22, 2026) |
As of October 15, 2026: Clinical trial NCT04879329 is currently recruiting participants. This phase2 study for bladder cancer is actively seeking new participants at 158 locations across the United States. The study is sponsored by Seagen, a wholly owned subsidiary of Pfizer. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT04879329 is actively recruiting participants as of October 15, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 158 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04879329 was last updated Jul 22, 2026 (July 22, 2026). HelloStudys verifies this status automatically.